Cargando…
Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host
Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies that is dependent on T-cell immunity and complement participation and mainly involves neuromuscular junctions. In this study, 30 patients with myasthenia gravis were selected and divided into pretreatment (Case group) and postt...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852828/ https://www.ncbi.nlm.nih.gov/pubmed/36687653 http://dx.doi.org/10.3389/fmicb.2022.1082565 |
_version_ | 1784872744461008896 |
---|---|
author | Zhao, Mingli Liu, Li Liu, Fanzhao Liu, Lei Liu, Zhijuan Gao, Yanli Cao, Jianxi |
author_facet | Zhao, Mingli Liu, Li Liu, Fanzhao Liu, Lei Liu, Zhijuan Gao, Yanli Cao, Jianxi |
author_sort | Zhao, Mingli |
collection | PubMed |
description | Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies that is dependent on T-cell immunity and complement participation and mainly involves neuromuscular junctions. In this study, 30 patients with myasthenia gravis were selected and divided into pretreatment (Case group) and posttreatment (Treatment group) and 30 healthy volunteers (CON group) were included. Among them, the treatment group was treated with Modified Buzhong Yiqi Decoction (MBZYQD), and the levels of antibodies such as AChR, Musk and Titin in blood and intestinal microbiota were compared before treatment (Case group), after treatment (Treatment group) and in healthy volunteers (CON group). The results showed that after treatment with MBZYQD, the antibody levels of AChR, MuSK, and Titin and the inflammatory factor level of IL-6, IL-1β, and IL-22 in MG patients decreased significantly and nearly returned to a healthy level. In addition, after treatment with MBZYQD, the diversity, structure and function of intestinal microorganisms in MG patients also recovered to a healthy level. At the phylum level, the relative abundance of Proteobacteria in the Case group increased significantly, accompanied by a significant decrease in the relative abundance of Bacteroides compared with that in the CON group, the relative abundance of Proteobacteria and Bacteroides in the Treatment group was similar to that in the CON group. At the genus level, the relative abundance of Shigella in the Case group was significantly increased, accompanied by a significant decrease in the relative abundance of Prevotella, and the relative abundance of Shigella and Prevotella in Treatment group was similar to that in the CON group. Moreover, the fluorobenzoate degradation pathway (KO00364) was significantly increased in the Case group, while this pathway was significantly decreased in the Treatment group. In conclusion, MBZYQD can improve the immune function of the host by regulating the diversity, structure and function of the intestinal microbiota to treat myasthenia gravis. |
format | Online Article Text |
id | pubmed-9852828 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98528282023-01-21 Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host Zhao, Mingli Liu, Li Liu, Fanzhao Liu, Lei Liu, Zhijuan Gao, Yanli Cao, Jianxi Front Microbiol Microbiology Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies that is dependent on T-cell immunity and complement participation and mainly involves neuromuscular junctions. In this study, 30 patients with myasthenia gravis were selected and divided into pretreatment (Case group) and posttreatment (Treatment group) and 30 healthy volunteers (CON group) were included. Among them, the treatment group was treated with Modified Buzhong Yiqi Decoction (MBZYQD), and the levels of antibodies such as AChR, Musk and Titin in blood and intestinal microbiota were compared before treatment (Case group), after treatment (Treatment group) and in healthy volunteers (CON group). The results showed that after treatment with MBZYQD, the antibody levels of AChR, MuSK, and Titin and the inflammatory factor level of IL-6, IL-1β, and IL-22 in MG patients decreased significantly and nearly returned to a healthy level. In addition, after treatment with MBZYQD, the diversity, structure and function of intestinal microorganisms in MG patients also recovered to a healthy level. At the phylum level, the relative abundance of Proteobacteria in the Case group increased significantly, accompanied by a significant decrease in the relative abundance of Bacteroides compared with that in the CON group, the relative abundance of Proteobacteria and Bacteroides in the Treatment group was similar to that in the CON group. At the genus level, the relative abundance of Shigella in the Case group was significantly increased, accompanied by a significant decrease in the relative abundance of Prevotella, and the relative abundance of Shigella and Prevotella in Treatment group was similar to that in the CON group. Moreover, the fluorobenzoate degradation pathway (KO00364) was significantly increased in the Case group, while this pathway was significantly decreased in the Treatment group. In conclusion, MBZYQD can improve the immune function of the host by regulating the diversity, structure and function of the intestinal microbiota to treat myasthenia gravis. Frontiers Media S.A. 2023-01-06 /pmc/articles/PMC9852828/ /pubmed/36687653 http://dx.doi.org/10.3389/fmicb.2022.1082565 Text en Copyright © 2023 Zhao, Liu, Liu, Liu, Liu, Gao and Cao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Zhao, Mingli Liu, Li Liu, Fanzhao Liu, Lei Liu, Zhijuan Gao, Yanli Cao, Jianxi Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host |
title | Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host |
title_full | Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host |
title_fullStr | Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host |
title_full_unstemmed | Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host |
title_short | Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host |
title_sort | traditional chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852828/ https://www.ncbi.nlm.nih.gov/pubmed/36687653 http://dx.doi.org/10.3389/fmicb.2022.1082565 |
work_keys_str_mv | AT zhaomingli traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost AT liuli traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost AT liufanzhao traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost AT liulei traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost AT liuzhijuan traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost AT gaoyanli traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost AT caojianxi traditionalchinesemedicineimprovesmyastheniagravisbyregulatingthesymbiotichomeostasisoftheintestinalmicrobiotaandhost |